Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the ONWARDS 1–5 trials
Authors' conclusion
Efficacy and hypoglycaemia outcomes of icodec versus once-daily comparators were generally consistent among adults with T2D, regardless of kidney function.
Study context
- Population
- Insulin-naive (ONWARDS 1, 3 and 5) and insulin-experienced (ONWARDS 2 and 4) adults aged ≥18 years with T2D, by kidney function subgroup (eGFR ≥90; 60-<90; 30-<60; <30 mL/min/1.73m2); eGFR <30 excluded in ONWARDS 1–4 but not ONWARDS 53,763 analysed
- Participants
- 3,765 participants
- Comparison
- Once-weekly insulin icodec vs once-daily basal insulin
Methodological detailssubgroup analysis by kidney function
- Subgroup analysis by kidney function
Primary result
As reported in the abstract
Change in HbA1c by kidney function subgroup · baseline to end of treatment
- No statistically significant treatment interactions by kidney function subgroup in ONWARDS 1, 3 and 5
- Icodec vs Once-daily basal insulin: P for interaction < 0.05 (ONWARDS 2 and 4, both)
Further findings
| Outcome | P value |
|---|---|
| HbA1c <7% without clinically significant or severe hypoglycaemiaNo statistically significant interactions | all p-interaction >0.05 |
Change in body weight by kidney function subgroup · baseline to end of treatment
- Comparable between treatment arms across kidney function subgroups
Mean weekly insulin dose, last 2 weeks of treatment
- No consistent trend by kidney function subgroup across trials
Safety
Combined clinically significant or severe hypoglycaemia rates
- No consistent trend by kidney function subgroup across trials
Original publication
Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the ONWARDS 1–5 trials. Diabetes Obes Metab. Published 10 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →